Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Japanese biopharmaceutical start-up seeks investment
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Senior Associate, International Business Advisory
|Project highlights||tumor antigen peptide vaccines - good safety and efficacy data|
The Japanese biopharmaceutical start-up is developing tumor antigen peptide vaccines and authorizing immunologic adjuvants. The tumor antigen peptide vaccines are tumor polypeptide antigens (HSP70/GPC3 peptides) which can be combined with three different types of white blood cells (HLA-A2402, HLA-A0201, HLA-A0206). The other component - immunologic adjuvants - have been recognized in clinical trials with good safety and efficacy data; it has already been applied for patent and is planning to conduct Phase 1 and Phase 2 clinical trials.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us